Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Becton Dickinson And Co And Lab21 Collaborate To Develop New Oncology Assays On BD MAX Platform


Monday, 15 Oct 2012 08:00am EDT 

Becton Dickinson And Co and Lab21 announced that they will collaborate to develop oncology assays for the BD MAX fully automated, bench-top molecular system. Under the terms of the collaboration, Lab21 will develop polymerase chain reaction-based assays on the BD MAX platform for a series of oncology markers. BD will be responsible for manufacturing and commercializing the tests worldwide. The first two assays will be designed to detect mutations in the KRAS and BRAF genes. These initial assays were selected because of their current importance in optimizing the management of cancer patients. The agreement also includes the development of nucleic acid extraction procedures from formalin-fixed paraffin-embedded tissue. The collaboration will develop BD's offering in personalized cancer diagnostics on the BD MAX system. 

Company Quote

117.06
0.58 +0.50%
28 Aug 2014